Vir Biotechnology, Inc. (VIR)

Market Cap	1.45B +51.9%
Revenue (ttm)	68.56M -7.6%
Net Income	-437.99M
EPS	-3.16
Shares Out	159.81M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,355,930
Open	8.92
Previous Close	9.06
Day's Range	8.92 - 9.27
52-Week Range	4.16 - 10.94
Beta	1.66
Analysts	Strong Buy
Price Target	19.63 (+116.67%)
Earnings Date	May 6, 2026

About VIR

Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company’s preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting va...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 11, 2019
• Employees: 367
• Stock Exchange: NASDAQ
• Ticker Symbol: VIR
• Website: https://www.vir.bio

Financial Performance

In 2025, Vir Biotechnology's revenue was $68.56 million, a decrease of -7.61% compared to the previous year's $74.21 million. Losses were -$437.99 million, -16.09% less than in 2024.

Analyst Summary

According to 8 analysts, the average rating for VIR stock is "Strong Buy." The 12-month stock price target is $19.63, which is an increase of 116.67% from the latest price.

Price Target

$19.63

(116.67% upside)

Analyst Consensus: Strong Buy